AKERO THERAPEUTICS INC (AKRO) Stock Price, Quote, News and Overview
NASDAQ:AKRO - Nasdaq - US00973Y1082 - Common Stock - Currency: USD
AKRO Quote, Performance and Key Statistics
49.38
-0.71 (-1.42%)
The current stock price of AKRO is 49.38 USD. In the past month the price decreased by -5.18%. In the past year, price increased by 98.63%.
AKRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.52 | 365.10B | ||
| AMGN | AMGEN INC | 13.59 | 159.41B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 147.24B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.19 | 100.87B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 62.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 70.53 | 40.01B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.92 | 34.78B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.29B | ||
| INSM | INSMED INC | N/A | 24.24B | ||
| NTRA | NATERA INC | N/A | 22.26B | ||
| BIIB | BIOGEN INC | 8.66 | 20.31B |
Related stock screener links
About AKRO
Company Profile
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Company Info
AKERO THERAPEUTICS INC
601 Gateway Boulevard, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Andrew Cheng
Employees: 63
Phone: 16504876488
AKERO THERAPEUTICS INC / AKRO FAQ
What is the stock price of AKERO THERAPEUTICS INC today?
The current stock price of AKRO is 49.38 USD. The price decreased by -1.42% in the last trading session.
What is the ticker symbol for AKERO THERAPEUTICS INC stock?
The exchange symbol of AKERO THERAPEUTICS INC is AKRO and it is listed on the Nasdaq exchange.
On which exchange is AKRO stock listed?
AKRO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AKERO THERAPEUTICS INC stock?
18 analysts have analysed AKRO and the average price target is 78.45 USD. This implies a price increase of 58.86% is expected in the next year compared to the current price of 49.38. Check the AKERO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AKERO THERAPEUTICS INC worth?
AKERO THERAPEUTICS INC (AKRO) has a market capitalization of 3.94B USD. This makes AKRO a Mid Cap stock.
How many employees does AKERO THERAPEUTICS INC have?
AKERO THERAPEUTICS INC (AKRO) currently has 63 employees.
What are the support and resistance levels for AKERO THERAPEUTICS INC (AKRO) stock?
AKERO THERAPEUTICS INC (AKRO) has a support level at 48.58 and a resistance level at 49.6. Check the full technical report for a detailed analysis of AKRO support and resistance levels.
Should I buy AKERO THERAPEUTICS INC (AKRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AKRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AKRO, evaluating the profitability, health, valuation and growth aspects
- AKERO THERAPEUTICS INC (AKRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AKERO THERAPEUTICS INC (AKRO) Sales and EPS estimates to see what analysts future expectations are.
- AKERO THERAPEUTICS INC (AKRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AKERO THERAPEUTICS INC (AKRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- AKERO THERAPEUTICS INC (AKRO) Stock Chart to make your own analysis
- AKERO THERAPEUTICS INC (AKRO) Latest news and press-releases to stay up to date.
Does AKERO THERAPEUTICS INC (AKRO) stock pay dividends?
AKRO does not pay a dividend.
When does AKERO THERAPEUTICS INC (AKRO) report earnings?
AKERO THERAPEUTICS INC (AKRO) will report earnings on 2025-11-06, before the market open.
What is the Price/Earnings (PE) ratio of AKERO THERAPEUTICS INC (AKRO)?
AKERO THERAPEUTICS INC (AKRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.8).
What is the Short Interest ratio of AKERO THERAPEUTICS INC (AKRO) stock?
The outstanding short interest for AKERO THERAPEUTICS INC (AKRO) is 11.32% of its float. Check the ownership tab for more information on the AKRO short interest.
AKRO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AKRO. When comparing the yearly performance of all stocks, AKRO is one of the better performing stocks in the market, outperforming 94.08% of all stocks.
AKRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AKRO. AKRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AKRO Financial Highlights
Over the last trailing twelve months AKRO reported a non-GAAP Earnings per Share(EPS) of -3.8. The EPS decreased by -11.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.31% | ||
| ROE | -24.86% | ||
| Debt/Equity | 0.03 |
AKRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to AKRO. The Buy consensus is the average rating of analysts ratings from 18 analysts.